These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 26563167)

  • 1. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
    Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
    J Clin Gastroenterol; 2016 Apr; 50(4):318-25. PubMed ID: 26368296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
    Zakko SF; Gordon GL; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
    Postgrad Med; 2016; 128(3):273-81. PubMed ID: 26861051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
    Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
    Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
    Lichtenstein GR; Barrett AC; Bortey E; Paterson C; Forbes WP
    Inflamm Bowel Dis; 2014 Aug; 20(8):1399-406. PubMed ID: 24874460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
    Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
    Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release mesalamine granules for ulcerative colitis.
    Love BL; Miller AD
    Ann Pharmacother; 2012 Nov; 46(11):1529-36. PubMed ID: 23115226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
    Ford AC; Khan KJ; Sandborn WJ; Hanauer SB; Moayyedi P
    Clin Gastroenterol Hepatol; 2012 May; 10(5):513-9. PubMed ID: 22083024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
    Miehlke S; Madisch A; Kupcinskas L; Petrauskas D; Böhm G; Marks HJ; Neumeyer M; Nathan T; Fernández-Bañares F; Greinwald R; Mohrbacher R; Vieth M; Bonderup OK;
    Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
    Gong Y; Zha Q; Li L; Liu Y; Yang B; Liu L; Lu A; Lin Y; Jiang M
    J Ethnopharmacol; 2012 Jun; 141(2):592-8. PubMed ID: 21911045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
    Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
    Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.
    Tong JL; Huang ML; Xu XT; Qiao YQ; Ran ZH
    J Dig Dis; 2012 Apr; 13(4):200-7. PubMed ID: 22435504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
    Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
    Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.